SEC Form 4 · accession 0001437749-16-028526
RESPONSE BIOMEDICAL CORP · RBM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lewis Shuster
Director
Period of report
Mar 24, 2016
Accepted (ET)
Mar 28, 2016 · 9:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000806888
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Share Unit Award (Right to Receive)F1 | $0.00 | Mar 24, 2016 | A | 36,764 | A | — | — | Common Stock | 36,764 | 36,764 | D |
| Stock Option (right to buy)F2,F3 | $0.85 | Mar 24, 2016 | A | 5,000 | A | — | Mar 23, 2026 | Common Stock | 5,000 | 5,000 | D |
Explanation of responses
- F1Reporting person has received an exempt award of Deferred Share Units ("DSUs") under the Issuer's Non-Employee Directors Deferred Share Unit Plan (the "Plan"). DSUs represent a right to receive shares of the issuer's common stock (or, in the sole discretion of the Issuer's Board of Directors following a Change in Control as defined in the Plan, cash, securities or a combination of cash and securities equal to the fair market value thereof) upon the reporting person's termination of service for the issuer. The DSUs are immediately vested and expire 90-days following the reporting person's Termination Date as defined in the Plan.
- F2Exercise prices shown are denominated in Canadian dollars.
- F3Subject to the reporting person's continued service as a director of the company through each vesting date, 100% of the shares subject to the option shall vest and become exercisable on March 24, 2017.